Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 26Gynecologic 2Thoracic 1Genitourinary 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 21Colorectal Neoplasms 14Lung Neoplasms 9Stomach Neoplasms 5Neoplasms 5Neoplasm Metastasis 5Colonic Neoplasms 5Triple Negative Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Small Cell Lung Carcinoma 4Rectal Neoplasms 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Esophageal Neoplasms 4Melanoma 3Carcinoma, Renal Cell 3Carcinoma, Pancreatic Ductal 3Peritoneal Neoplasms 2Mesothelioma 2Fallopian Tube Neoplasms 2Endometrial Neoplasms 2Vipoma 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Thymoma 1Spinocerebellar Degenerations 1Somatostatinoma 1Sezary Syndrome 1Pseudomyxoma Peritonei 1

Interventions

pembrolizumab 12Nivolumab 4fludarabine 3Gemcitabine 3Drug Therapy 3Cisplatin 3spartalizumab 2budigalimab 2Injections 2Fluorodeoxyglucose F18 2Cyclophosphamide 2zenocutuzumab 1venetoclax 1ulixertinib 1tocilizumab 1tislelizumab 1seribantumab 1saracatinib 1rovalpituzumab tesirine 1pertuzumab 1pemigatinib 1niraparib 1neratinib 1milademetan 1margetuximab 1erdafitinib 1entrectinib 1cobimetinib 1cediranib 1bemarituzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cholangiocarcinoma × Leucovorin × Thoracic × Clear all
NCT06607185 2026-05-26

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Eli Lilly and Company

Phase 1 Active not recruiting
750 enrolled
GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡